GNP 1 GPI 2 GAP 3 Shamla 4

Global NAPI Pharmaceuticals (GNP)

Global NAPI Pharmaceuticals (GNP) was established as a private investment company in 1997, designed and licensed for pharmaceutical formulations production in Egypt. Since that time, with a dramatic progress and respected presence in the pharmaceuticals market, GNP not only introduced to the Egyptian market its own branded generic formulations, but also established several license agreements with multinational pharmaceutical companies like MSD, Sanofi, Pierre Fabre, Elerte and others, in addition to, manufacturing agreements with Bayer Consumer Care, Novartis, Pfizer, Roche, Boehringer Ingelheim and Stada for local Egyptian market supply.
GNP products are covering a wide range of therapeutic areas, with more than 100 brand names in tablets, capsules, solutions, syrups, ointments, creams, gels, and suppositories forms. Many of these brands are market leader in their classes. GNP is ranked No.9 within the pharmaceutical companies in Q3 /2014.

Global Pharmaceutical Industries (GPI)

Global Pharmaceutical Industries (GPI), a sister company to GNP, was inaugurated in 2013 for the production of sterile injectable products.
GPI, a state of the art manufacturing facility, is currently operating in preparation, filling and packaging of both solutions and lyophilized products. Two Production lines are available for ampoules (1-5 ml, solution or freeze-dried) and for vials (1-100 ml, solution or freeze-dried)
Production started in August 2013 with many of GPI & GNP injectable brands. Contract manufacturing to Pfizer, Amoun, Sandoz, Ranbaxy & Roche were established and many of their products are already available in the Egyptian market.

Global Advanced Pharmaceuticals (GAP)

Global Advanced Pharmaceuticals (GAP)- Currently Known as Pharmapack- is a mega project of 7 production modules for different pharmaceutical forms including Soft Gelatin Capsules,
Uni-dose Inhalation form, Ophthalmic Preparations, Oncology Products, Cephalosporins, in addition to, traditional forms like Solid, Liquid & Semisolid forms.
Land area is 63,000 m2, layout and design was done by a German consultant
Construction started in February 2013, and production is expected to start by 2016.

SHAMLA Pharmaceutical Industries

SHAMLA Pharmaceutical Industries is a joint venture project for pharmaceuticals production of solids, liquids and semisolids dosage forms in King Abdullah Industrial Zone in Jeddah, Kingdom of Saudi Arabia.
Construction started in August 2013, and planned to be ready for production by the end of 2015.  



Copyright © 2017 Global Napi Pharmaceuticals.All rights reserved.
Designed & Developed by | VisionApps Team.